Physician profile
Eric B Sklar
NPI 1316939267
$51,663.39
in general payments reported to CMS, 2019-2025
30 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,151 · 2020: $1,802 · 2021: $12K · 2022: $8,125 · 2023: $16K · 2024: $12K · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Consulting Fee: $11K · Food and Beverage: $1,753 · Travel and Lodging: $1,562 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,447.50 |
| Consulting Fee | $10,646.56 |
| Food and Beverage | $1,752.95 |
| Travel and Lodging | $1,561.64 |
| Education | $223.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $17,559.89 | 2022-2024 | |
| Harmony Biosciences LLC | $11,871.11 | 2021-2025 | Wakix |
| Axsome Therapeutics, INC. | $9,724.13 | 2023-2024 | Sunosi |
| Biohaven Pharmaceuticals, INC. | $8,488.06 | 2020-2021 | |
| Inspire Medical Systems, INC. | $963.36 | 2022-2025 | Inspire |
| Supernus Pharmaceuticals, INC. | $682.71 | 2019-2021 | |
| Abbvie INC. | $481.96 | 2021-2025 | Botox, Ubrelvy |
| Allergan, INC. | $387.63 | 2019-2021 | |
| Genzyme Corporation | $284.47 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $213.64 | 2019-2020 | |
| Ucb, INC. | $163.08 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $147.19 | 2019 | |
| Biogen, INC. | $104.85 | 2019-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $103.32 | 2023 | Lumryz |
| Lundbeck LLC | $82.83 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $74.37 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $38.71 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $36.18 | 2019 | |
| Amgen INC. | $32.52 | 2019 | |
| Emd Serono, INC. | $32.40 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $27.40 | 2020 | |
| Upsher-Smith Laboratories LLC | $24.08 | 2021 | |
| Bausch Health US, LLC | $22.64 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $21.56 | 2019 | |
| Aquestive Therapeutics, INC. | $20.06 | 2020 | |
| Neurocrine Biosciences, INC. | $18.32 | 2021 | |
| Ironshore Pharmaceuticals INC. | $16.71 | 2019 | |
| Medtronic, INC. | $14.93 | 2022 | |
| Neurelis, INC. | $13.40 | 2024 | Valtoco |
| Celgene Corporation | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Sklar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.